World-first gene-editing therapy for blood disorders approved for NHS use
Hundreds of people in England with life-limiting sickle cell disease are set to benefit from the treatment.
Hundreds of people in England with life-limiting sickle cell disease are set to benefit from the treatment.
The drug was initially rejected by the NHS because of cost concerns.
NICE says it cannot recommend the new treatment as it needs further evidence to prove its effectiveness.